Serum hs-cTnT elevation (≥14 ng/l) in acute ischemic stroke patients was significantly associated with an increased risk of death or major disability at 3 months (OR 2.22; 95% CI 1.10-4.48; P=0.03).
Cohort (n=516)
Does elevated serum hs-cTnT predict death or major disability in patients with acute ischemic stroke?
Elevated serum hs-cTnT on admission is an independent predictor of death or major disability at 3 months in patients with acute ischemic stroke.
Effect estimate: OR 2.22 (95% CI 1.10-4.48)
p-value: p=0.03
BACKGROUND: Cardiac autonomic dysfunction caused by ischemic stroke might lead to an adverse outcome. Elevated high sensitivity cardiac troponin (hs-cTnT) is a marker of cardiac disease, it can elevate in acute stroke patients. The aim of the present study was to investigate association between serum hs-cTnT with prognosis among patients with acute ischemic stroke. METHODS: Five hundred and sixteen patients (mean age 66.19 ± 10.11) with acute ischemic stroke underwent a comprehensive clinical investigation and serum hs-cTnT activity test. All patients were followed up for 3 months. The prognosis was death or major disability (modified Rankin Scale score ≥ 3) at 3 months after acute ischemic stroke. RESULTS: 22.87% (118/516) of patients had serum hs-cTnT elevation (≥14 ng/l). Compared with normal hs-TnT group, the incidence of insular stroke (adjusted odds ratio, 2.84; 95% confidence interval, 1.48-4.17; P = 0.001) were more likely in patients with hs-cTnT elevation. In fully adjusted models, there was an association between serum hs-cTnT elevation and death (adjusted odds ratio, 3.14; 95% confidence interval, 1.16-8.49; P = 0.02) and major disability(adjusted odds ratio, 2.07; 95% confidence interval, 1.04-4.51; P = 0.04), and composite outcome(adjusted odds ratio,2.22;95% confidence interval,1.10-4.48; P = 0.03). CONCLUSIONS: Higher levels of serum hs-cTnT were independently associated with increased risk of death or major disability after stroke onset, suggesting that serum hs-cTnT may have prognostic value in poor outcomes of ischemic stroke.
He et al. (Mon,) conducted a cohort in Acute ischemic stroke (n=516). Serum hs-cTnT elevation (≥14 ng/l) vs. Normal hs-cTnT was evaluated on Death or major disability (modified Rankin Scale score ≥ 3) at 3 months (OR 2.22, 95% CI 1.10-4.48, p=0.03). Serum hs-cTnT elevation (≥14 ng/l) in acute ischemic stroke patients was significantly associated with an increased risk of death or major disability at 3 months (OR 2.22; 95% CI 1.10-4.48; P=0.03).